open access

Vol 2, No 4 (2006)
Review paper
Published online: 2006-09-26
Get Citation

The role of chemotherapy in malignant ovarian germ cell tumors’ treatment

Magdalena Miedzińska-Maciejewska, Paweł Kubik, Mariusz Bidziński
Onkol. Prak. Klin 2006;2(4):165-170.

open access

Vol 2, No 4 (2006)
REVIEW ARTICLES
Published online: 2006-09-26

Abstract

Malignant ovarian germ cell tumors account for less than 5% of all malignant ovarian tumors. They are very aggressive and occur primarily in girls and young women. Malignant germ cell tumors can be subdivided into different histopathological types as follows dysgerminoma, yolk sac tumor, immature teratoma, embryonal carcinoma, ovarian choriocarcinoma and mixed germ cell tumor, which differ not only in morphology and histopathology, but they have also different natural behaviour and outcomes. In the last years, thanks to the introduction of highly effective cytostatic drugs to their treatment, the prognosis have dramatically improved. From definitely fatal disease with a high failure and death-rate they have moved up to the group of malignancies with the excellent outcomes. Correctly performed surgical intervention and early intensive chemotherapy account to above 80% of survival rates. In addition, thanks to a great chemosensitivity of these tumors group it is possible to conduct less excessive surgeries and retain the fertility and normal hormonal activities. Nowadays the main point of interest are not only the possibilities of more effective treatment and searching of predicitive factors but reduction of toxicity and quality of life improvement. And normal hormonal activity and child bearing potential after the treatment is now the routine part of standard protocol for the management plan.

Abstract

Malignant ovarian germ cell tumors account for less than 5% of all malignant ovarian tumors. They are very aggressive and occur primarily in girls and young women. Malignant germ cell tumors can be subdivided into different histopathological types as follows dysgerminoma, yolk sac tumor, immature teratoma, embryonal carcinoma, ovarian choriocarcinoma and mixed germ cell tumor, which differ not only in morphology and histopathology, but they have also different natural behaviour and outcomes. In the last years, thanks to the introduction of highly effective cytostatic drugs to their treatment, the prognosis have dramatically improved. From definitely fatal disease with a high failure and death-rate they have moved up to the group of malignancies with the excellent outcomes. Correctly performed surgical intervention and early intensive chemotherapy account to above 80% of survival rates. In addition, thanks to a great chemosensitivity of these tumors group it is possible to conduct less excessive surgeries and retain the fertility and normal hormonal activities. Nowadays the main point of interest are not only the possibilities of more effective treatment and searching of predicitive factors but reduction of toxicity and quality of life improvement. And normal hormonal activity and child bearing potential after the treatment is now the routine part of standard protocol for the management plan.
Get Citation

Keywords

malignant germ cell tumors; ovarian tumors; treatment; chemotherapy; BEP

About this article
Title

The role of chemotherapy in malignant ovarian germ cell tumors’ treatment

Journal

Oncology in Clinical Practice

Issue

Vol 2, No 4 (2006)

Article type

Review paper

Pages

165-170

Published online

2006-09-26

Bibliographic record

Onkol. Prak. Klin 2006;2(4):165-170.

Keywords

malignant germ cell tumors
ovarian tumors
treatment
chemotherapy
BEP

Authors

Magdalena Miedzińska-Maciejewska
Paweł Kubik
Mariusz Bidziński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl